VEGFA and cancer: Presently, the majority of anti-angiogenic agents approved for cancer treatment rely on targeting vascular endothelial growth factor (VEGF) actions, given that VEGF signaling is widely acknowledged as the principal promoter of angiogenesis (Lopes-Coelho et al., 2021).